Mannatech Q3 Profit Is a $10.9M Non-Cash Tax Benefit; Going Concern Doubt Persists
MTEX has more than doubled off its 52-week low of $3.8 on light trading volume (0.2× avg).
Summary
Mannatech's headline Q3 profit of $8.9 million is a non-cash tax benefit; pre-tax it lost $1.95 million on sales down 14.7%, and management still flags going-concern doubt.
Key Events · Earnings and Guidance · MTEX
-
Q3 Profit Is Non-Cash Tax Benefit
Net income of $8.9 million ($4.61 per share) includes a $10.9 million non-cash deferred tax benefit from remeasuring foreign withholding-tax liabilities; pre-tax the company lost $1.954 million.
-
Sales Decline Accelerates
Q3 net sales fell 14.7% to $24.9 million from $29.2 million; nine-month sales were $76.4 million, down 6.1%.
-
Going Concern Doubt Persists
Management states substantial doubt about the ability to continue as a going concern within one year continues to exist; the October 2026 Nasdaq equity cure was non-cash and did not address liquidity.
-
Cash and Operating Cash Flow
Cash and equivalents fell to $5.4 million from $6.2 million at December 31, 2025; nine-month operating cash flow was positive $0.085 million versus negative $2.674 million a year earlier.
Analysis · MTEX · Life Sciences
The $8.9 million quarterly profit ($4.61 per share) is almost entirely an accounting entry: a $10.9 million non-cash deferred tax benefit from remeasuring foreign withholding-tax liabilities. Strip that out and Mannatech lost $1.95 million before taxes in the quarter, with sales down 14.7% to $24.9 million. Management explicitly says substantial doubt about continuing as a going concern still exists as of this report — the October restructuring that satisfied Nasdaq's $2.5 million equity rule added no cash and does not fix liquidity. Cash slipped to $5.4 million from $6.2 million at year-end. The one genuine improvement is operating cash flow, roughly breakeven at $0.1 million for nine months versus a $2.7 million burn a year ago, helped by cost cuts. Directors also extended $2.7 million of 16% insider notes to March 31, 2028, buying time but not capital.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTEX was trading at $8.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.3M. The 52-week trading range was $3.80 to $12.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.